Megha Mehrotra
Navi Mumbai, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells.
Journal: Biochemical and biophysical research communications
Published: April 06, 2026
A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.
Journal: Medical oncology (Northwood, London, England)
Published: December 01, 2025
Alpelisib enhances cisplatin mediated cytotoxicity in non-mutated, PIK3CA-dependent high-grade serous ovarian cancer.
Journal: Journal of ovarian research
Published: November 16, 2025
Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.
Journal: Advances in experimental medicine and biology
Published: May 28, 2024
Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells.
Journal: Journal of experimental & clinical cancer research : CR
Published: March 18, 2024
The Power of Kinetic Inertness in Improving Platinum Anticancer Therapy by Circumventing Resistance and Ameliorating Nephrotoxicity.
Journal: Angewandte Chemie (International ed. in English)
Published: March 21, 2023
Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics.
Journal: Diagnostics (Basel, Switzerland)
Published: December 05, 2022
Homo and Heterotypic Cellular Cross-Talk in Epithelial Ovarian Cancer Impart Pro-Tumorigenic Properties through Differential Activation of the Notch3 Pathway.
Journal: Cancers
Published: June 06, 2022
Predicting response to platinum and non-platinum drugs through bioluminescence resonance energy transfer (BRET) based bio-molecular interactions in platinum resistant epithelial ovarian cancer.
Journal: Translational oncology
Published: June 10, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026